-

The Future of AI & Electrophysiology Takes Center Stage at Heart Rhythm 2025 with Vektor Medical

  • Rhythm Theater Expert Panel Saturday AM Will Discuss the Role of AI-Powered Analysis and PFA
  • Visit Vektor at Adjacent Booths #1523 & #1622

SAN DIEGO--(BUSINESS WIRE)--Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, will showcase its transformative vMap technology at Heart Rhythm 2025, taking place April 25–27 in San Diego. Through live demonstrations at adjacent booths (#1523 and #1622), scientific abstract presentations, and a highly anticipated Rhythm Theater session featuring leading electrophysiologists, Vektor will offer attendees a firsthand look at how vMap is being integrated into clinical workflows to support more informed, efficient, and effective ablation strategies.

This unique, data-driven approach is helping EPs accelerate diagnosis, enhance procedural accuracy, and improve outcomes across the arrhythmia care spectrum.

Share

vMap is the only FDA-cleared, AI-based arrhythmia analysis solution that uses a standard 12-lead ECG to non-invasively localize arrhythmia sources, including both focal and fibrillation-type rhythms. This unique, data-driven approach is helping EPs accelerate diagnosis, enhance procedural accuracy, and improve outcomes across the arrhythmia care spectrum.

Experience vMap in Action

Visit Booths #1523 and #1622 (side-by-side) to explore how vMap is redefining arrhythmia source localization. See firsthand how physicians use the technology to improve outcomes, streamline workflows, and expand access to effective treatment. Schedule a one-on-one demo with the Vektor team here.

Rhythm Theater Session

“AI and PFA: A Complementary Approach to Arrhythmia Treatment”
Saturday, April 26 | 9:15 – 10:00 a.m. | Rhythm Theater 2

Moderated by Dr. Devi Nair, Director of Cardiac Electrophysiology at St. Bernards Heart & Vascular, this session will spotlight how AI-powered ECG analysis elevates the standard of care in EP labs. The panel will also explore how vMap integrates with pulsed field ablation (PFA) and other advanced treatment strategies.

Panelists and discussion topics include:

  • Dr. Gery Tomassoni, Baptist Health Lexington: Non-PV Driver Ablation with vMap and Upcoming Clinical Studies
  • Dr. Benjamin D’Souza, Penn Medicine: vMap’s Role in VT Ablation and Procedural Outcomes
  • Dr. Anish Amin, OhioHealth: Integrating vMap into AF Ablation Procedures with PFA

Scientific Abstract Presentations

  • Mapping of Unstable Scar Mediated Ventricular Tachycardias: A Novel Technique
    Saturday, April 26 | 9:30 – 11:30 a.m.
    Dr. Faris Haddadin
    Abstract Pavilion
  • Optimizing Procedural Techniques for Improved Ablation Outcomes
    Sunday, April 27 | 8:00 – 9:00 a.m.
    “Prospective Non-Invasive Artificial Intelligence-Based CT and ECG Localization of Scar-Based Ventricular Arrhythmias” - Dr. Gordon Ho
    Oral Abstract Hub 1 – Sails Pavilion

“vMap addresses a critical gap in arrhythmia care,” said Rob Krummen, CEO of Vektor Medical. “Electrophysiologists across the U.S. are using vMap to guide ablation strategies with greater confidence, and the results are gaining attention. At HRS, we are proud to showcase that impact through live demos and by amplifying the voices of the physicians using this technology every day. As we prepare to launch multiple key clinical studies, including our pivotal randomized trial, we are deepening the clinical foundation for broader adoption. This is a pivotal moment—for Vektor and the future of electrophysiology.”

About vMap®

vMap is the only FDA-cleared, non-invasive AI-powered solution for mapping arrhythmias, utilizing just a 12-lead ECG. vMap localizes arrhythmia sources for focal and fibrillatory arrhythmias, including atrial fibrillation. By unlocking actionable insights contained within a standard 12-lead ECG, vMap enables physicians to rapidly and accurately locate arrhythmia source locations. Backed by extensive clinical evidence, vMap not only improves patient outcomes but also reduces procedure time, optimizing workflow across the entire arrhythmia care pathway.

About Vektor Medical

Headquartered in San Diego, Vektor Medical is on a mission to revolutionize arrhythmia care for millions affected by atrial fibrillation and other arrhythmias. Through its AI-powered, non-invasive arrhythmia analysis technology, vMap, the company aims to improve cardiac ablation outcomes, optimize workflows, and increase procedural efficiency. For more information about vMap and Vektor Medical, please visit www.vektormedical.com.

Connect with Vektor Medical on LinkedIn and X.

Contacts

Media Contact
Stacey Holifield
Levitate
(617) 233-3873
vektor@levitatenow.com

Vektor Medical


Release Versions

Contacts

Media Contact
Stacey Holifield
Levitate
(617) 233-3873
vektor@levitatenow.com

Social Media Profiles
More News From Vektor Medical

Vektor Medical’s vMap Surpasses 2,000 Procedures, Driving a New Standard in Arrhythmia Care

SAN DIEGO--(BUSINESS WIRE)--Vektor Medical today announced its vMap® system has been used in more than 2,000 procedures in the U.S., a milestone that underscores its rapid adoption by electrophysiologists (EPs) and hospitals seeking to improve procedural efficiency, reduce repeat interventions, and deliver better patient outcomes. vMap, developed with AI and designed to localize both focal and fibrillation-type arrhythmias, delivers actionable insights in all four chambers of the heart in less...

First Patients Enrolled in IMPRoVED-AF Study Using vMap, a Non-Invasive ECG-Based Tool Designed to Guide More Effective AF Ablation

SAN DIEGO--(BUSINESS WIRE)--Vektor Medical, a medical technology company transforming standard ECG data into actionable insights that guide arrhythmia care, today announced that Baptist Health Lexington has enrolled the first patients in the IMPRoVED-AF clinical study. Baptist Health Lexington, a 434-bed acute care hospital, is a long-time leader in innovative approaches to treat heart disease and related conditions. IMPRoVED-AF is a prospective, randomized, controlled, international, multi-cen...

Vektor Medical Announces Post-Market Study Evaluating Benefit of AI-Powered Analysis to Identify and Ablate Non-Pulmonary Vein AF Targets

SAN DIEGO--(BUSINESS WIRE)--Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced the initiation of the IMPRoVED AF clinical study designed to evaluate the benefit of utilizing AI-driven mapping to identify and ablate non-pulmonary vein electrical drivers implicated in persistent and recurrent atrial fibrillation (AF). IMPRoVED AF (artificial Intelligence Mapping and ablation of non-PulmonaRy Vein Electrical Drivers of AF) is a prospective, randomi...
Back to Newsroom